4.7 Review

MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis?

Journal

GENOME MEDICINE
Volume 1, Issue -, Pages -

Publisher

BIOMED CENTRAL LTD
DOI: 10.1186/gm85

Keywords

-

Funding

  1. National Institutes of Health [HL080133]
  2. American Heart Association [09GRNT2250567]
  3. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL095707, R01HL080133] Funding Source: NIH RePORTER

Ask authors/readers for more resources

MicroRNAs (miRNAs) represent a class of small, non-coding RNAs that negatively regulate gene expression via degradation or translational inhibition of their target mRNAs. Recent studies have identified that miR-145 is the most abundant miRNA in normal arteries and vascular smooth muscle cells (VSMCs), and its expression is significantly downregulated in dedifferentiated VSMCs and atherosclerotic arteries. miR-145 plays a critical role in modulating VSMC phenotype. Because phenotypic modulation of VSMCs is an initial cellular event in the development of atherosclerosis, miRNAs, and miR-145 in particular, may represent new therapeutic targets for atherosclerosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available